Psyence Biomedical Ltd (PBM) Stock Price, Quote & News

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress dis...

Industry: Biotechnology

Sector: Healthcare

Phone: 416 346 7764

Website: www.psyencebiomed.com

Address:

121 Richmond Street West, Penthouse Suite, 1300, Toronto, Canada

WinnersParadise May. 15 at 4:46 PM

$ATCH $LASE $PBM $APVO cnmc

0 · Reply

J4y000 May. 15 at 4:32 PM

$PBM $IXHL

0 · Reply

Jbjb90 May. 15 at 2:07 PM

$PBM

1 · Reply

SonOfSea May. 15 at 1:49 PM

$PBM Hope, this will fly soon.

0 · Reply

Jbjb90 May. 15 at 1:31 PM

$PBM imagine as a debt free company, they were able to announce a partnership to supply a company with ibogaine in return for a steady stream of cash to fund their research and not need to dilute or make offerings

0 · Reply

Jbjb90 May. 15 at 1:25 PM

$PBM this is the direction I was hoping theyd take, lets fucking go

0 · Reply

CHItraders May. 15 at 1:23 PM

PSYENCE BIOMED FIRES UP IBOGAINE OPS IN AFRICA $PBM is activating ibogaine production and manufacturing capabilities in Africa via its PsyLabs investment while sending execs to the US to meet researchers, institutions, and regulators. 🔹 Claims to be one of the few outfits globally producing natural pharma-grade ibogaine at scale under GMP conditions 🔹 Leadership road trip to advance psychedelic medicine research and policy talks 🔹 Focused on nature-derived compounds for clinical and therapeutic use

0 · Reply

Jbjb90 May. 15 at 1:22 PM

$PBM https://www.stocktitan.net/news/PBM/psyence-bio-med-announces-u-s-strategic-engagement-initiative-tvu0twvkeiw4.html

0 · Reply

letitride1 May. 15 at 1:16 PM

$PBM $12

0 · Reply

ProfProfit May. 15 at 1:27 AM

$PBM Where the hell is this POS going??

0 · Reply

Psyence Biomedical announces U.S. engagement initiative focused on ibogaine

May 15, 2026, 9:15 AM EDT - 8 hours ago

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Apr 23, 2026, 7:00 AM EDT - 22 days ago

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

2026-04-20T12:19:33.000Z - 25 days ago

Psyence Biomedical provides update on position in global ibogaine market

Apr 20, 2026, 7:42 AM EDT - 25 days ago

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

2026-04-18T00:33:00.000Z - 27 days ago

Why Is Psyence Biomedical Stock (PBM) Up Today?

2026-04-17T19:16:22.000Z - 4 weeks ago

Psyence Biomedical Ltd trading resumes

2026-04-17T19:12:01.000Z - 4 weeks ago

Psyence Biomedical Ltd trading halted, volatility trading pause

2026-04-17T13:26:00.000Z - 4 weeks ago

Psyence acknowledges reports on U.S. action to advance Ibogaine research

Apr 17, 2026, 9:15 AM EDT - 4 weeks ago

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Apr 8, 2026, 9:15 AM EDT - 5 weeks ago

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Mar 11, 2026, 9:15 AM EDT - 2 months ago

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

2026-03-03T14:22:48.000Z - 2 months ago

Psyence Biomedical announces export of psilocybin to Australia

Mar 3, 2026, 9:15 AM EST - 2 months ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Feb 20, 2026, 5:20 PM EST - 2 months ago

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

2026-02-17T14:27:42.000Z - 3 months ago

Psyence Biomedical announces results of annual, special meeting

Feb 17, 2026, 9:15 AM EST - 3 months ago

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

2026-02-13T23:35:11.000Z - 3 months ago

Psyence Biomedical board approves put option agreement with PsyLabs

Feb 13, 2026, 6:30 PM EST - 3 months ago

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

2026-02-11T14:20:57.000Z - 3 months ago

Psyence Biomedical announces settlement of shareholder litigation

Feb 11, 2026, 9:15 AM EST - 3 months ago

Psyence BioMed Announces Settlement of Shareholder Litigation

Jan 28, 2026, 6:30 PM EST - 3 months ago

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Jan 22, 2026, 1:42 PM EST - 4 months ago

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Jan 20, 2026, 7:19 AM EST - 4 months ago

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Jan 12, 2026, 8:30 AM EST - 4 months ago

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Jan 5, 2026, 9:15 AM EST - 4 months ago

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Dec 19, 2025, 7:00 AM EST - 5 months ago

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Dec 9, 2025, 7:00 AM EST - 5 months ago

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Nov 25, 2025, 7:00 AM EST - 6 months ago

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Nov 20, 2025, 7:00 AM EST - 6 months ago

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Nov 12, 2025, 7:00 AM EST - 6 months ago

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Nov 6, 2025, 7:00 AM EST - 6 months ago

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Nov 3, 2025, 7:00 AM EST - 6 months ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Aug 28, 2025, 8:00 AM EDT - 9 months ago

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 31, 2025, 7:30 AM EDT - 10 months ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jun 25, 2025, 5:00 PM EDT - 11 months ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 11 months ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 8:30 AM EDT - 11 months ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 17, 2025, 8:00 AM EDT - 11 months ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

May 27, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 1, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Apr 17, 2025, 7:17 PM EDT - 1 year ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 9:39 AM EDT - 1 year ago

Psyence Group Announces Share Consolidation

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 10, 2025, 11:18 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 1 year ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Dec 27, 2024, 4:05 PM EST - 1 year ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 23, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 17, 2024, 8:37 AM EST - 1 year ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 7:30 AM EST - 1 year ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 10, 2024, 7:30 AM EST - 1 year ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 6, 2024, 11:06 AM EST - 1 year ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 3, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Nov 19, 2024, 4:05 PM EST - 1 year ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 12, 2024, 4:30 PM EST - 1 year ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Oct 31, 2024, 9:30 AM EDT - 1 year ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Oct 25, 2024, 9:42 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

WinnersParadise May. 15 at 4:46 PM

$ATCH $LASE $PBM $APVO cnmc

0 · Reply

J4y000 May. 15 at 4:32 PM

$PBM $IXHL

0 · Reply

Jbjb90 May. 15 at 2:07 PM

$PBM

1 · Reply

SonOfSea May. 15 at 1:49 PM

$PBM Hope, this will fly soon.

0 · Reply

Jbjb90 May. 15 at 1:31 PM

0 · Reply

Jbjb90 May. 15 at 1:25 PM

$PBM this is the direction I was hoping theyd take, lets fucking go

0 · Reply

CHItraders May. 15 at 1:23 PM

0 · Reply

Jbjb90 May. 15 at 1:22 PM

$PBM https://www.stocktitan.net/news/PBM/psyence-bio-med-announces-u-s-strategic-engagement-initiative-tvu0twvkeiw4.html

0 · Reply

letitride1 May. 15 at 1:16 PM

$PBM $12

0 · Reply

ProfProfit May. 15 at 1:27 AM

$PBM Where the hell is this POS going??

0 · Reply

SonOfSea May. 14 at 3:30 PM

$PBM way from $12 to $4, Any possibilities for $4 to $12?

1 · Reply

RuddyRolls May. 14 at 1:48 AM

$PBM next catalyst 2b read out I guess. Any others?

1 · Reply

FAFO_Trades May. 13 at 11:26 PM

$SMX Hey market maskers- Stop beating up my "fantastic five"! • $GNS • $SMX (not so fantastic, I know) 😢 • $AIXI • $PBM • $TNON

3 · Reply

Jbjb90 May. 13 at 9:49 PM

$PBM strange amount of post market volume

0 · Reply

Jbjb90 May. 13 at 9:32 PM

$PBM thats pbH not PBM

0 · Reply

KL2222 May. 13 at 9:00 PM

$PBM

0 · Reply

Tradetime3472 May. 13 at 8:51 PM

$PBM Im bullish here, but that must’ve been a coordinated pump and dump

0 · Reply

Jack_Horway May. 13 at 8:49 PM

$PBM its so weird...and exciting

0 · Reply

longjohntrader May. 13 at 8:44 PM

$PBM again down. Why this Spike?

0 · Reply

Stephen_7 May. 13 at 8:36 PM

$PBM Big green candle!!!!!!!!!!!! $$$$$$$$$$$$$ WOW

0 · Reply

Buysellbkr May. 13 at 8:35 PM

$PBM getting play

0 · Reply

AlertsAndNews May. 13 at 8:35 PM

$PBM headline here Prestige Consumer Healthcare Announces agreement To Acquire LaCorium Health, A Leader In Australian Therapeutic Skin Care For 150M

0 · Reply

Market Cap	5.28M
Revenue (ttm)	0.00
Net Income (ttm)	1.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	135,708
Avg Vol	3,207,986
Day's Range	N/A - N/A
Shares Out	1.02M
Stochastic %K	8%
Beta	1.78
Analysts	Strong Buy
Price Target	N/A